ArticleEuropean journal of case reports in internal medicine2026
Unmasking Cytomegalovirus Colitis: A Case of Haemorrhagic Colitis in a Patient with Chronic Myeloid Leukaemia on Dasatinib.
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.American journal of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine kinase inhibitors (TKIs) are the first-line treatment for chronic myeloid leukaemia (CML) with BCR-ABL1 translocation. Dasatinib, a second-generation TKI, is associated with a wide range of adverse effects such as myelosuppression, pleural effusion, diarrhoea, and haemorrhagic colitis in up to 40% of patients. Additionally, its off-target immunomodulatory effects on natural killer cells and T lymphocytes may lead to the reactivation of latent infections, including cytomegalovirus (CMV), a known cause of colitis. Case report: We present a case of CMV-associated haemorrhagic colitis in a 69-year-old woman with CML in complete remission, who was being treated with dasatinib. She was admitted to our hospital with a 1-month history of generalized weakness, light-headedness, and intermittent haematochezia. On presentation, she was hypotensive and tachycardic due to haemorrhagic shock. Urgent colonoscopy revealed multiple small ulcers and erosions in the rectum, sigmoid, and transverse colon with signs of active bleeding, which were managed with haemostatic clips. Rectal biopsy initially showed mild, non-specific chronic inflammation. Dasatinib was discontinued due to suspected drug-related colitis. However, post-discharge immunohistochemistry revealed localized CMV inclusions, prompting readmission and initiation of valganciclovir therapy. Conclusion: This case highlights the importance of considering opportunistic infections such as CMV in CML patients receiving TKIs. Given the overlapping clinical and endoscopic features of CMV and dasatinib-induced colitis, histopathological evaluation is essential for accurate diagnosis and timely management. LEARNING POINTS: In immunosuppressed patients being treated with dasatinib, haemorrhagic colitis can mask an underlying infection.Tissue biopsy constitutes a key tool for promptly diagnosing cytomegalovirus colitis, enabling clinicians to start treatment early and thus prevent adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.